GlassScriptPhysician profile
Vinutha Raj
NPI 1437144979
$5,652.00
in general payments reported to CMS, 2019-2025
20 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $949 · 2021: $830 · 2022: $770 · 2023: $666 · 2024: $1,001 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,367.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $579.18 | 2019-2025 | Xifaxan |
| Amgen INC. | $550.08 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $541.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $483.04 | 2019-2025 | |
| Novo Nordisk INC | $379.32 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $367.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.33 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $272.61 | 2019-2023 | Steglatro, Steglujan |
| Lilly USA, LLC | $193.44 | 2019-2023 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $175.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $150.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.40 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $63.34 | 2019-2021 | |
| Abbott Laboratories | $34.59 | 2023-2024 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.62 | 2019-2025 | Austedo Xr |
| Astellas Pharma US INC | $27.01 | 2019 | |
| Amarin Pharma, INC. | $26.61 | 2019-2020 | |
| Esperion Therapeutics, INC. | $25.98 | 2021 | |
| Renalytix Ai, INC. | $16.82 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinutha Raj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.